Novartis could soon face generic competition for Entresto after judge's ruling.

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Find insight on Germany’s pharmaceutical industry, Novartis and more in the latest Market Talks covering Health Care.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...